At LUMICKS, our dream is to unlock single-molecule and -cell analysis.
Understanding the root causes of diseases, such as cancer, at the molecular level is one of the greatest scientific challenges of today. Expanding the knowledge of biological processes that are at the basis of diseases is key for prevention and for developing future cures. We aim at creating an environment for researchers to perform high quality, high throughput single-molecule and -cell experiments in the most accessible manner.
Understanding the root causes of diseases, such as cancer, at the molecular level is one of the greatest scientific challenges of today. Expanding the knowledge of biological processes that are at the basis of diseases is key for prevention and for developing future cures. We aim at creating an environment for researchers to perform high quality, high throughput single-molecule and -cell experiments in the most accessible manner.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Phone: +31 20 220 0817
Total raised: $93.03M
Founded date: 2014
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.04.2021 | Series D | $93.03M | - |
Mentions in press and media 12
| Date | Title | Description |
| 14.10.2024 | Last week recap: European tech companies raised over €956M, around 73% collected by 10 biggest deals | Last week, we tracked more than 70 tech funding deals worth over €956 million, and over 5 exits, M&A transactions, rumours, and related news stories across Europe. In Q3 2024, European tech companies raised €11 billion over 891 deals. C... |
| 09.02.2022 | Paris-based Lauxera Capital Partners sets high stakes on health tech with $300 million maiden fund | Investment firm based in Paris and San Francisco, Lauxera Capital Partners announced the final closing of its first fund, Lauxera Growth I, at more than €260 million (approximately $300 million), making it one of the leading European funds ... |
| 29.12.2021 | These are the 21 biggest funding rounds of 2021 in the Netherlands | Over the last decade, the startup ecosystem’s value in the Netherlands has been rising fast. With a competitive talent pool, a complicated yet connected economic structure, and a booming tech sector, the Netherlands has enough reasons to be... |
| 24.06.2021 | Looking for a job in Amsterdam? These awesome startups that recently raised funding are hiring right now | Amsterdam’s startup ecosystem has also been making quite a splash globally. According to a recent report by Dealroom, Amsterdam’s tech ecosystem hit €100B in value (€187B if you include Booking), making it the third most valuable hub in Eur... |
| 19.04.2021 | Amsterdam's Lumicks picks up $93M | Lumicks, a developer of single-molecule analysis technologies for cancer research and immunotherapy, has raised a $93 million Series D. Farallon Capital Management and Lauxera Capital Partners led the round, which the startup will use for r... |
| 16.04.2021 | Lumicks Raises $93M in Series D Financing | Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding. The round was led by new investors Farallon Ca... |
| 16.04.2021 | LUMICKS raises $93 million in Series D financing | Amsterdam, the Netherlands – LUMICKS, a leading, next generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D ... |
| 16.04.2021 | Amsterdam-based Lumicks raises €77.6M to provide instruments to reveal unique molecular, cellular interactions | With an exponential increase in the rate of progress in biological research, the demand to understand how biological processes occur at a molecular level is becoming increasingly important. And, according to Amsterdam-based Lumicks, it want... |
| 16.04.2021 | TG Therapeutics prepares to approach regulators with MS drug; Investors bet $93M on a life sciences tools company | Gearing up for a battle with pharma giants, TG Therapeutics says it’s nearly ready to approach regulators with its CD20 drug for multiple sclerosis. The biotech read out results from two Phase III trials at AAN, which show... |
| 27.06.2018 | New partnership aims to accelerate discovery of potential new drugs | New partnership aims to accelerate discovery of potential new drugs 27-06-2018 LUMICKS collaborates with AstraZeneca and the University of Cambridge to form the first ever Center of Excellence for Dynamic Single-Molecule Analysis for Accele... |
Show more